Cholesterol metabolism pathways – are the intermediates more important than the products? by Yuqin, Wang et al.
STATE-OF-THE-ART REVIEW
Cholesterol metabolism pathways – are the intermediates
more important than the products?
Yuqin Wang, Eylan Yutuc and William J. Griffiths
Swansea University Medical School, UK
Keywords
cholestenoic acids; COVID-19; G protein-
coupled receptors; glutamate receptors;
inborn errors of metabolism; mass
spectrometry; nuclear receptors; oxysterols;
sterols
Correspondence
W. J. Griffiths and Y. Wang, Swansea
University Medical School, ILS1 Building,
Singleton Park, Swansea SA2 8PP, UK
Every cell in vertebrates possesses the machinery to synthesise cholesterol
and to metabolise it. The major route of cholesterol metabolism is conver-
sion to bile acids. Bile acids themselves are interesting molecules being
ligands to nuclear and G protein-coupled receptors, but perhaps the inter-
mediates in the bile acid biosynthesis pathways are even more interesting
and equally important. Here, we discuss the biological activity of the differ-
ent intermediates generated in the various bile acid biosynthesis pathways.
We put forward the hypothesis that the acidic pathway of bile acid biosyn-
thesis has primary evolved to generate signalling molecules and its
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utilisation by hepatocytes provides an added bonus of producing bile acids
to aid absorption of lipids in the intestine.
Introduction
Cholesterol metabolism has been studied for many
decades [1–3]. In mammals, the products of cholesterol
metabolism are bile acids, and steroid hormones and
their metabolites [4,5]. While bile acids and steroid
hormones are of undoubted importance, in recent
years interest has shifted to intermediates in their
biosynthesis and to a category of molecules known as
oxysterols [6–9]. Oxysterols can be defined as oxidised
forms of cholesterol or of its precursors. They are
formed in the first steps of cholesterol metabolism,
mostly by cytochrome P450 (CYP) enzymes [3,4,10].
They can also be formed via nonenzymatic reactions
both in vivo and ex vivo [11–13]. Many oxysterols have
biological activity being ligands to, for example
nuclear receptors, G protein-coupled receptors
(GPCRs) and glutamate receptors [6,8,9,13].
There are many areas of biology in which oxysterols
play a role. At the very beginning of life, oxysterols are
key molecules in embryonic development acting along
with other sterols to transmit the Hedgehog (Hh) signal
[14], a key pathway for fate determination of stem cells
and progenitor cells. Oxysterols activate this pathway
by binding to Smoothened (Smo), a GPCR found at the
cell membranes of primary cilia [15]. Oxysterols also
appear as key molecules for definition of neural progen-
itor fate by activating the liver X receptors (LXRs)
[16,17], while cholestenoic acids, downstream metabo-
lites of oxysterols, are important for survival or death
of motor neurons [18]. Oxysterols have been also linked
to cancer, through overactivation of Hh signalling and
via many other mechanisms [9,15,19]. While some oxys-
terols are oncogenic, others appear to be protective
against cancer [9]. Perhaps unsurprisingly as oxidised
forms of cholesterol, oxysterols are implicated in the
atherosclerotic process being found in atherosclerotic
plaques [20]. Oxysterols also appear to be involved in
the immune response, having either inflammatory or
anti-inflammatory properties [21–24], and are generated
in response to both bacterial infection and viral infec-
tion [25–27]. There is growing evidence that certain
oxysterol may inhibit infection by the SARS-CoV-2
virus (COVID-19) [28–31].
Accepting that oxysterols are critical biological
molecules, it is important to remember that oxysterols
are a family of molecules, where small changes in
geometry can lead to the difference between activity
and inactivity. It is also crucial to be aware that oxys-
terol concentrations are very often determined follow-
ing a base hydrolysis step where oxysterols esterified to
fatty acids are released, so what is actually being deter-
mined is the sum of the free molecules and their esteri-
fied versions. Usually, oxysterol esters are more
abundant than the nonesterified molecules, but it is the
nonesterified molecules that are biologically active.
Today, mass spectrometry (MS) in combination with
liquid chromatography (LC), that is LC-MS, or with
gas chromatography (GC), that is GC-MS, is almost
exclusively used for oxysterol measurements [32–37].
In the following sections, we will attempt to summarise
the current ‘state of play’ in oxysterol research and
endeavour to highlight key unresolved questions. We
arrange the review by rotating around the major pri-
mary oxysterols derived from cholesterol (Fig. 1),
looking at biological activity and downstream metabo-
lites.
25-hydroxycholesterol (25-HC)
25-HC is an unusual oxysterol in that cholesterol 25-
hydroxylase (CH25H, EC:1.14.99.38) is not a CYP
enzyme but is a member of a small group of proteins
that utilise a diiron cofactor to catalyse hydroxylation
[38]. Note, 25-HC can also be formed as a minor side
product in reactions catalysed by CYP3A4 (EC:1.14.
14, CYP3A11 in mouse), CYP27A1 and CYP46A1
[4,10,39,40]. In normal circumstances, the level of 25-
HC is low in tissues and in the circulation [33,41];
however, upon bacterial or viral infection CH25H
(Ch25h in mouse) is upregulated in activated macro-
phages with the consequent enhanced formation of 25-
HC [23,25–27,42–44]. 25-HC is reported to be anti-in-
flammatory and antiviral [21,26,27,45], and this
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information has stimulated much interest in 25-HC in
relation to SARS-CoV-2 [29–31]. CH25H is an inter-
feron (IFN)-stimulated gene, IFN being induced by
Toll-like receptor (TLR) 3 and TLR4 ligands upon
bacterial infection [43,44]. Upon SARS-CoV-2 viral
infection, IFN, CH25H and other IFN-stimulated
genes are upregulated [29,31]. Zang et al. identified 25-
HC as a potent inhibitor of SARS-CoV-2 replication,
explaining this by 25-HC blocking cholesterol export
from the late endosome/lysosome compartment and
restricting SARS-CoV-2 spike protein catalysed mem-
brane fusion [29]. Interestingly, inhibition of Nie-
mann–Pick C1 protein (NPC1), the cholesterol
transporter that transports cholesterols out of late
endosomes/lysosomes, also inhibited SARS-CoV-2
replication, supporting the theory that blocking choles-
terol export from late endosomes/lysosomes inhibits
viral replication (Fig. 2) [29].
Deficiency in NPC1 (95% of cases) or NPC2 (5% of
cases) leads to Niemann–Pick type C disease. While
NPC1 protein transports cholesterol across the
organelle membrane, NPC2 protein is soluble and car-
ries nonesterified cholesterol to the NPC1 transporter
[46]. Niemann–Pick type B disease shows some clinical
and biochemically similarities to the type C disease
[47,48], but is genetically different, in that the type B
disease results from mutations in the SMPD1 gene,
and deficiency in the enzyme activity of acid sphin-
gomyelinase (EC:3.1.4.12). It has been suggested that
acid sphingomyelinase stimulates NPC2-mediated
cholesterol export by converting sphingomyelin to cer-
amide in the inner membranes of late endosomes [49],
and the consequence of its deficiency is enhanced
cholesterol content of lysosomes. In support of the
hypothesis of Zang et al. [29] that blocking cholesterol
export from late endosomes/lysosomes inhibits viral
replication, Carpinteiro et al. [50] have recently found
that inhibiting acid sphingomyelinase prevents SARS-
CoV-2 uptake by epithelial cells, although their expla-
nation for the involvement of acid sphingomyelinase in
SARS-CoV-2 infection was at the level of ceramide in
the outer leaflet of the plasma membrane. An
Fig. 1. Structure of primary oxysterols and downstream metabolites. Cholesterol is shown in red, cholesterol precursors in purple and
oxysterols in black. Enzymes are written in blue, and nonenzymatic oxidation is indicated by [O] in green. In 7b,26-diHC and 26H,7O-C,
R1 = OH and R2 = H, while in 7b,25-diHC and 25H,7O-C, R1 = H and R2 = OH.
3The FEBS Journal (2021) ª 2021 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
Y. Wang et al. Cholesterol metabolism
alternative explanation for the antiviral activity of 25-
HC against SARS-CoV-2 is provided by Wang et al.
[31] who found CH25H to be induced by SARS-CoV-
2 in vitro, and suggested the antiviral activity of 25-
HC to be via inhibition of membrane fusion through
depletion of plasma membrane cholesterol as a conse-
quence of activation of acyl-CoA cholesterol acyltrans-
ferase (EC:2.3.1.26), an enzyme that converts free
cholesterol to its cholesteryl ester. Hence, one sug-
gested mechanism of 25-HC antiviral action is through
cholesterol accumulation in the late endosomes, block-
ing membrane fusion and restricting the virus to this
compartment [29], while a second mechanism is
through depletion of plasma membrane cholesterol
inhibiting viral membrane fusion and entry [31]. A
combination of both mechanisms would suggest that
25-HC can block membrane fusion and viral entry by
reducing the available nonesterified cholesterol in
membranes by inhibiting transport of cholesterol out
of the late endosome/lysosome compartment and
through activation of acyl-CoA cholesterol acyltrans-
ferase. In Fig. 2, we present a simplified cartoon repre-
sentation of the involvement of 25-HC in preventing
viral infection.
It is interesting to note that neither of the antiviral
mechanisms discussed above invoked inhibition of
SREBP-2 (sterol regulatory-binding protein-2) process-
ing or activation of LXRs, two key regulators of cellu-
lar cholesterol status. 25-HC suppresses cholesterol
biosynthesis by binding to the endoplasmic resident
protein INSIG (insulin-induced gene) tethering
SREBP-2 and its escort protein SCAP (SREBP cleav-
age-activating protein) within the endoplasmic reticu-
lum and preventing transport of SREBP-2 to the
Golgi for processing to its active form as the master
transcription factor for the expression of genes of the
cholesterol biosynthesis pathway [51]. Blanc et al. [26]
proposed this mechanism to partially explain the
antiviral action of macrophage produced 25-HC
towards a broad range of viruses, while Dang et al.
[45] suggested inhibition of SREBP-2 processing by
25-HC prevents AIM2 (absent in melanoma 2) inflam-
masome activation in macrophages and provides an
anti-inflammatory circuit that prevents spurious AIM2
inflammasome activation. 25-HC is also a ligand to
the LXRs [52,53], LXR activation leads to upregula-
tion of SREBP-1c and fatty acid synthesis [54], and
also of the ABC (ATP-binding cassette) transporters
Fig. 2. Simplified cartoon representation of the involvement of 25-HC in protection against SARS-CoV-2 infection. (A) The virus enters the
cell via endocytosis. Viral RNA escapes from the endosome/lysosome compartment by membrane fusion in concert with NPC2–NPC1-
mediated export of cholesterol. 25-HC inhibits NPC1-mediated cholesterol export and traps the virus in the late endosome/lysosome
compartment [29]. Alternatively, (B) 25-HC may activate acyl-CoA cholesterol acyltransferase and sequester cholesterol as the ester,
depleting the availability of plasma membrane nonesterified cholesterol required for membrane fusion and viral entry [31].
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including ABCA1, ABCG1 and the cholesterol carrier
protein apolipoprotein E (APOE) [55,56]. In combina-
tion, the activation of LXR leads to removal of free
cholesterol from cells by esterification, transport out of
the cell by ABC transporters and its ultimate removal
via apolipoproteins in the circulation. Hence, LXR
activation by 25-HC, and also 25-HC binding to
INSIG, may provide additional mechanisms for inhibi-
tion of COVID-19 infection through depletion of
membrane cholesterol.
There is now good cell-based evidence that 25-HC is
protective against SARS-CoV-2 through a mechanism
involving depletion of membrane cholesterol. The mul-
tiple biological activities of 25-HC suggest that 25-HC
may have a multipronged mechanism for depleting
membrane cholesterol and hence defence against the
virus. It is interesting to note that total 25-HC (sum of
biologically active nonesterified 25-HC and its inactive
esterified form) is elevated in patients suffering mild
SARS-CoV-2 [28], suggesting the successful defence
against the virus by 25-HC may be via its enhanced
biosynthesis.
Key issues to resolve
Despite the availability of vaccines against SARS-
CoV-2, which are being offered to citizens in rich
countries of the developed world, it is questionable
whether people in the developing world will be availed
such a ‘luxury’. It is also unknown at present how
effective the vaccines will be over time. Hence, alterna-
tive low-cost strategies still require exploration. Once
such alternative is treatment with the BCG vaccine,
which is known to activate the TLR4 [57] and will pre-
sumably enhance the expression of IFN [58], so should
theoretically enhance CH25H expression and the
biosynthesis 25-HC, leading to protection against
SARS-CoV-2.
7a,25-dihydroxycholesterol (7a,25-diHC), 7b,25-
dihydroxycholesterol (7b,25-diHC) and 25-hydroxy-7-
oxocholesterol (25H,7O-C)
7a,25-diHC is the major metabolic product of 25-HC
formed in a reaction catalysed by CYP7B1 (EC:1.14.
14.29) [59]. It can also be formed from 7a-hydroxyc-
holesterol (7a-HC) in a reaction catalysed by CYP3A4
(EC:1.14.14) in human and CYP3A11 (EC:1.14.14) in
mouse [60]. 7a,25-diHC does not show antiviral activ-
ity [29], and neither has it been shown to have an
effect on SREBP-2 processing or LXR activation.
However, 7a,25-diHC is a ligand towards the GPCR
Epstein–Barr virus-induced gene 2 (EBI2 or GPR 183)
[22,24] and acts as a chemoattractant to B and T cells
expressing the receptor. Hence, in contrast to 25-HC,
which can be regarded as anti-inflammatory [21,45],
7a,25-diHC is a proinflammatory lipokine. Further
metabolism of 7a,25-diHC leads to 7a,25-dihydroxyc-
holest-4-en-3-one (7a,25-diHCO) catalysed by the
enzyme hydroxysteroid dehydrogenase (HSD) 3B7
(EC:1.1.1) and further to 7a,25-dihydroxy-3-oxoc-
holest-4-en-26-oic acid (7a,25-diH,3O-CA), probably
catalysed by CYP27A1 [61]. Interestingly, 7a,25-
diH,3O-CA has been found to be of reduced abun-
dance in cerebrospinal fluid (CSF) from patients with
Alzheimer’s disease (AD) [62], linking the pathology
with proinflammatory 7a,25-diHC.
Like 7a,25-diHC, 7b,25-diHC is also a ligand to
GPR183 [22]. However, until recently pathways for the
formation of 7b,25-diHC were unknown [10,48,63,64].
Low levels of both 7b-hydroxycholesterol (7b-HC) and
7-oxocholesterol (7-OC) are always present in analysis
of cholesterol-derived oxysterols from biological sam-
ples [65]. However, the fact that both molecules can be
formed from cholesterol via ex vivo autoxidation reac-
tions makes interpretation regarding their formation
difficult, as similar reactions can also occur endoge-
nously [11]. Convincing evidence for the endogenous
nature of 7b-hydroxy and 7-oxo metabolites of choles-
terol has come from analysis of plasma from people
with Niemann–Pick type C disease [47,48,66–70]. Jiang
et al. provided data showing elevation of 7-OC, and
also of cholestane-3b,5a,6b-triol, in plasma from Nie-
mann–Pick type C patients [68]. While more recently,
we found elevated levels of both these two cholesterol
derivatives and also 7b-HC in plasma of patients suf-
fering from both Niemann–Pick type C and type B
disease [48]. How can we be sure that these are
endogenous molecules, not artefacts generated by
ex vivo autoxidation of cholesterol? Strong evidence
for their endogenous nature would be downstream
enzymatic products also evident in plasma or urine
from Niemann–Pick patients. In fact, Alvelius et al.
found unusual 7-oxo- and 7b-hydroxy bile acids in
serum and urine from a Niemann–Pick type C patient
in 2001 [66], and these identifications were confirmed
by Maekawa et al. [71], and by Clayton and col-
leagues, who also identified a bile acid derived from
cholestane-3b,5a,6b-triol [70]. Further evidence for the
in vivo nature of 7b-HC and 7-OC was the discovery
of an entire metabolic pathway from these molecules
to 3b,7b-dihydroxychol-5-enoic and 3b-hydroxy-7-oxo-
chol-5-enoic acids [48]. In patients with Niemann–Pick
disease, it is likely that 7b-HC and 7-OC are derived
by free radical oxidation of cholesterol [48,66]. Once
formed, 7-OC and 7b-HC are interconvertible through
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the HSD11B enzymes [72,73]. HSD11B1 (EC:1.1.1) is
the 7-OC reductase, and HSD11B2 (EC:1.1.1), the 7b-
HC dehydrogenase. Both 7b-HC and 7-OC are sub-
strates for CH25H, giving 7b,25-diHC and 25H,7O-C,
respectively, and the two products can be intercon-
verted by HSD11B enzymes [63]. Importantly, 7b,25-
diHC will act as a chemoattractant and activator of
GPR183 but 25H,7O-C will not [22,63].
However, 25H,7O-C itself is a biologically active
molecule, binding and activating the GPCR protein
Smo [64], a member of the Frizzled class of GPCRs.
Smo plays a part in the Hh signalling pathway, its
activation leading to Hh signalling through Gli
(glioma-associated oncogene homolog) transcription
factors. The Hh pathway is essential for proper cell
differentiation, and defects in the pathway lead to
dysmorphology and cancer. Other key proteins in the
Hh pathway are patched-1 (Ptch1), a sterol transport
protein structurally related to NPC1 [74], and the
Hh ligand, for example Sonic hedgehog (SHH) post-
translationally modified with cholesterol [75]. Like
Niemann–Pick disease, Smith–Lemli–Opitz syndrome
(SLOS) is an autosomal recessive monogenetic disor-
der presenting with elevated 7b-HC and 7-OC in
plasma and tissues [64,76,77]. SLOS also presents
with dysmorphology and phenocopies defective Hh
signalling [78]. 25H,7O-C is present at elevated levels
in plasma from SLOS patients [64], perhaps acting
as a modulator of Smo in competition with other
sterol activators. 7b,25-diHC will also activate Smo
and is also found in plasma from SLOS patients
[64]. It is likely that the mechanisms behind the
biosynthesis of 7b,25-diHC and 25H,7O-C in Nie-
mann–Pick disease and SLOS are different. In SLOS,
there is a deficiency in 7-dehydrocholesterol reductase
(DHCR7, EC:1.3.1.21), one of the final enzymes in
the cholesterol biosynthesis pathways [79], and the
consequence of this is a build-up in 7-dehydrocholes-
terol (7-DHC). Like cholesterol, 7-DHC is a sub-
strate for CYP7A1 (EC:1.14.14); however, the
enzyme products are different, in that the product of
CYP7A1 oxidation of 7-DHC is 7-OC rather than
7a-HC, which is formed from cholesterol [76,80].
Hence, elevated levels of 7-OC in SLOS are a likely
consequence of CYP7A1 oxidation of 7-DHC. As
discussed above, 7-OC can be reduced to 7b-HC by
HSD11B1 and both can be oxidised to give a 25-hy-
droxy product, that is 25H,7O-C and 7b,25-diHC,
respectively. We have proposed pathways by which
25H,7O-C and 7b,25-diHC can be metabolised fur-
ther to 3b,7b,25-trihydroxycholest-5-enoic acid and
ultimately the C24 bile acid 3b,7b-dihydroxychol-5-
enoic acid [64].
Key issues to resolve and new ideas
GPR183 has been shown to direct the movement of
activated B cells expressing this receptor to outer folli-
cle regions of secondary lymphoid organs as required
for mounting a normal B-cell response to immune
challenge. 7a,25-diHC, 7b,25-diHC and also 7a,(25R)
26-dihydroxycholesterol (7a,26-diHC) all act as
chemoattractants to B and T cells expressing GPR183.
However, the gradient of 7a/b,25-diHC or 7a,26-diHC
has yet to be measured across lymph nodes to add fur-
ther evidence to the involvement of these oxysterols in
the immune response. One attractive concept is that
high levels of 7a,25-diHC in the lymph node outer fol-
licle attract B cells to mount the inflammatory
response, while 7a,26-diHC, derived from the circula-
tion, reverses the motion, thereby switching off the
immune response. Measurements of these oxysterols in
tissue should now be possible with the advent of oxys-
terol mass spectrometry imaging (MSI) [81]. With
respect to Hh signalling, Smo and oxysterols, it is
unclear how in vitro activity of oxysterols translates to
the situation in vivo, as besides oxysterols, cholesterol
will also bind to and activate Smo [75]. If cholesterol
rather than oxysterols is the true regulator of the Hh
signal, the question is how can such an abundant
sterol have signalling functions? Perhaps the answer
lies in measuring cholesterol and oxysterol levels in
primary cilia, the locality of Smo during the signalling
event. Such experiments should now be possible with
the advent of sterol-MSI and will answer the question
of whether oxysterols and/or cholesterol dictate Hh
signalling [81].
24-hydroxycholesterol (24-HC)
There are two isomers of 24-HC, 24S-HC and 24R-
HC. The 24S-HC epimer is dominant in man and
mouse with 24R-HC normally constituting of only
about 10% of the total in the circulation [82]. 24S-HC,
or cerebrosterol, is as the name suggests mostly syn-
thesised in brain [36,83]. The enzyme responsible for
24S-hydroxylation of cholesterol is CYP46A1 (EC:1.
14.14.25), which is mostly expressed in neurons [40].
24S-HC acts as a transport form of cholesterol provid-
ing a route for removal of excess cholesterol from
brain by crossing the blood–brain barrier, something
that cholesterol itself cannot do [36]. Once extracere-
bral, 24S-HC can be sulfated, glucuronidated or con-
verted to bile acids [84–86]. The 24-hydroxycholesterol
7a-hydroxylase is CYP39A1 (EC:1.14.14.26), required
to synthesise primary bile acids from 24S-HC, and is
mostly expressed in liver [87].
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No inborn error of metabolism has been found
resulting from a deficiency in CYP46A1 activity, and
the Cyp46a1/ mouse is viable, showing a compara-
tively mild phenotype with deficiencies in spatial, asso-
ciative and motor learning, and in hippocampal long-
term potentiation (LTP) [88,89]. Interestingly, in these
mice the defect in cholesterol metabolism in brain is
compensated by its reduced biosynthesis, the overall
level of cholesterol in brain being unchanged in the
Cyp46a1/ mouse compared with control [90,91].
24S-HC, like 25-HC, is a ligand to the LXRs [52,53]
and to INSIG [51], and it is also a modulator of the
N-methyl-D-aspartate receptors (NMDARs) [92] and
of Smo [93]. It is perhaps significant that 24S-HC, via
NMDARs, enhances the ability of subthreshold stim-
uli to induce LTP [92], considering that the absence of
24S-HC biosynthesis in the Cyp46a1/ mouse is
linked with a defect in LTP [89].
As 24S-HC is generated almost exclusively by neu-
rons in brain, its concentration in CSF and plasma
has been explored as a marker of neurodegeneration
[94]. In early stage disease, one might predict an initial
rise in 24S-HC, as neuronal loss leads to enhanced
availability of cholesterol, the substrate for CYP46A1,
but at later stages a decay in 24S-HC as ever-increas-
ing numbers of neurons, and hence CYP46A1
enzymes, is lost from brain. This can make data inter-
pretation challenging unless samples are well-stratified.
This is illustrated below.
In a recent study, Bj€orkhem et al. [95] found 24S-
HC to be elevated in CSF from early Parkinson’s
disease (PD) patients in comparison with controls.
The same investigators had previously found that
CSF 24S-HC levels correlate with PD disease pro-
gression [96]. In contrast to the situation in CSF, the
level of 24S-HC in plasma was not found to differ
between PD patients and controls [96]. These data
suggest that elevated 24S-HC in CSF is a marker of
neurodegeneration. In patients with AD, 24S-HC is
again elevated in CSF, and this is also true of
patients with mild cognitive impairment, but as with
PD no differences were found in plasma levels of
24S-HC [97]. Interestingly, 24S-HC in CSF was
found to increase according to APOE4 (apolipoprotein
E 4) status, patients with two APOE4 alleles having
the highest 24S-HC content of CSF [97]. However, in
plasma from severely affected AD patients the same
investigators found the 24S-HC to cholesterol ratio
to be decreased in AD [98], presumably as a conse-
quence of loss of CYP46A1 expressing neurons. In a
separate study, 24S-HC was found to be increased in
plasma of AD patients, but the levels to negatively
correlate with the severity of dementia [99]. Clearly,
care must be exercised in stratifying patient samples
to maximise the mechanistic insight provided by ana-
lytical data. Note, in these studies total 24S-HC was
measured, that is the sum of esterified and nonesteri-
fied 24S-HC.
Levels of 24S-HC have also been measured in
plasma of patients with Huntington’s disease (HD),
and concentrations found to vary according to disease
severity. Leoni et al. [100] measured 24S-HC in a
major study of 150 samples and found that 24S-HC
was elevated in an early progression HD group com-
pared with controls, but reduced compared with con-
trols in a latter progression HD group. These data
were at variance with an earlier study performed by
Leoni et al. who found 24S-HC to be reduced in HD
plasma at all disease states [101].
The CSF and plasma measurements discussed above
were all for total 24-HC, which constitutes the sum of
nonesterified and esterified 24-HC. Usually, the nones-
terified, biologically active molecules constitute only
about 20% of the total [34]. In the circulation, oxys-
terols are esterified with fatty acids in a reaction catal-
ysed by the enzyme lecithin–cholesterol acyltransferase
(LCAT, EC:2.3.1.43) present in HDL particles. CSF
lipoproteins tend to be small and spherical ( 10–
20 nm)-like plasma HDL [102], and human CSF
contains LCAT at levels corresponding to  2.5%
that of plasma LCAT [103]; however, the very minor
levels of nonesterified 24-HC (0.05 ngmL1 cf.
1.5 ngmL1esterified) in CSF indicate that this is suf-
ficient to esterify most of the nonesterified 24S-HC
that is present [62,104].
Major unresolved questions
In combination, the data presented above lead to
the conclusion that metabolism of cholesterol to
24S-HC is essential for brain health. However, is
24S-HC per se an essential oxysterol? Evidence from
studies on the Cyp46a1/ mouse suggests that it is
the flow through the cholesterol biosynthesis path-
way that is essential rather than 24S-HC itself
[88,89]. However, 24S-HC is a modulator of the
NMDARs, and a ligand to INSIG, LXRs and Smo,
at least in vitro, and it is difficult to define its exact
importance in activating these pathways as multiple
other oxysterols (and sterols) have similar effects on
these receptor proteins. A second important question
is how good is 24S-HC as a marker of neurodegen-
eration? From the studies mentioned above, it is
very important to have well-stratified groups to see
a statistical effect. Is this of diagnostic value? The
jury is still out.
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24S,25-epoxycholesterol (24S,25-EC)
24S,25-EC is one of the most efficacious endogenous
LXR ligands [52,53]. It is an unusual oxysterol in that
the mechanism of its formation involves cholesterol
precursors [105,106]. There are two likely pathways:
(a) 24S,25-EC may be synthesised in parallel to the
Bloch pathway of cholesterol biosynthesis but with
squalene epoxidase (SQLE, also named squalene
monooxygenase, EC:1.14.14.17) introducing two oxy-
gen atoms, one to give a 2,3S-epoxide and a second to
give a 22S,23-epoxide, to the squalene skeleton rather
than just one to give the 2,3S-epoxide. The two
branches then proceed in parallel to give 24S,25-EC
and cholesterol, respectively, the only difference being
that 24-dehydrocholesterol reductase (DHCR24, EC:1.
3.1.72) is absent from the pathway to generate 24S,25-
EC [6,105,107]. Lanosterol synthase (LSS, EC:5.4.99.7)
is the enzyme that will cyclase both the squalene
mono- and di-epoxides, and its reduced activity will
encourage di-epoxide formation and ultimately that of
24S,25-EC. (b) The alternative pathway to 24S,25-EC
is via CYP46A1 catalysed oxidation of desmosterol
[106].
24S,25-EC is seldom characterised in biological sam-
ples [33,65], and this is a consequence of its compara-
tively low abundance and the labile nature of the
24S,25-epoxy group. However, it has been analysed in
studies, which do not include an acid or base hydroly-
sis step [15–17,81,93,108–110]. In comparison with
other oxysterols, 24S,25-EC appears to be particularly
prevalent in brain during development, perhaps a con-
sequence of a high rate of cholesterol biosynthesis
[16,17,109–111]. 24S,25-EC acts as a ligand towards
LXRs [52,53], and Theofilopoulos et al. have generated
compelling evidence that 24S,25-EC, acting through
LXRs, promotes midbrain dopaminergic neurogenesis
[16,17]. Besides acting as an LXR ligand, 24S,25-EC
will also bind to INSIG and repress cholesterol synthe-
sis [51]. A more recently uncovered activity of 24S,25-
EC is as a ligand to Smo and activator of the Hh sig-
nalling pathway [15,93,112]. Cilia are protuberances
on the outside of cells, which are required for Smo to
transduce Hh signals. Smo accumulates in cilia, and
cilia-associated sterols promote this accumulation and
Hh signalling. In search for sterols, which may activate
the Hh pathway, Raleigh et al. [15] investigated the
oxysterols enriched in cilia isolated from sea urchin.
One of the oxysterols found was 24S,25-EC. 24S,25-
EC was found to bind to the extracellular cysteine-rich
domain (CRD) of Smo and activate Smo in a dose-de-
pendent manner. Interestingly, 24S,25-EC also acti-
vated Hh signalling through mutant Smo missing the
CRD [15]. Molecular docking studies suggested
24S,25-EC also bound to a cytoplasmic binding pocket
and mutation studies indicated that Smo activation by
24S,25-EC was via both binding sites [15]. Ptch1 is key
protein involved in inhibition of the Hh pathway, act-
ing as a sterol pump to deplete membranes of sterols.
In an effort to identify sterols linked to Hh signalling,
Qi et al. purified Ptch1 protein and identified 24S,25-
EC as one of the oxysterols co-purified with Ptch1
[93]. They found evidence for 24S,25-EC bound to the
7-transmembrane region of Smo and to be more effec-
tive at activating Hh signalling than other sterols [93].
In combination, the data of Raleigh et al. and Qi et al.
establish 24S,25-EC as a ligand of Smo that can bind
to multiple binding pockets and activate Hh signalling
[15,93]. The biological activities of 24S-HC and
24S,25-EC appear to overlap in that both activate
LXRs, inhibit cholesterol biosynthesis via INSIG and
repression of SREBP-2 processing, and both are
ligands to Smo. 24S-HC and 24S,25-EC are abundant
in brain, and we speculate that brain biology has built
a layer of redundancy in that CYP46A1 expressed in
neurons and SQLE expressed in glia can each direct
synthesis of the biologically active 24S-oxidised sterols,
that is 24S-HC and 24S,25-HC, respectively. Perhaps
this explains the comparatively mild phenotype of the
Cyp46a1/ mouse.
Key issue
The 24S,25-EC to cholesterol ratio is comparatively
high during brain development [16,17,109–111]. This
leads us to speculate that during brain development
24S,25-EC acts as an in vivo ligand to Smo and con-
trols Hh signalling and Hh-linked development.
(25R)26-Hydroxycholesterol (26-HC)
26-HC, more commonly known by the nonsystematic
name 27-hydroxycholesterol (27-HC), is the first inter-
mediate in the ‘acidic’, also known as the ‘alternative’,
pathway of bile acid biosynthesis [2,4,10]. It is synthe-
sised from cholesterol by CYP27A1 (EC:1.14.15.15)
and metabolised further to 3b-hydroxycholest-5-en-
(25R)26-oic acid (3b-HCA) or to 7a,(25R)26-dihydrox-
ycholesterol (7a,26-diHC) by CYP27A1 and CYP7B1,
respectively. 3b-HCA and 7a,26-HC are both biologi-
cally active, the former as a ligand towards LXRs
[18,113], and the latter as a ligand to GPR183 (see
above) [22]. 26-HC is in its own right an LXR ligand,
although a comparatively weak agonist [53]. 26-HC is
also a selective oestrogen receptor modulator (SERM)
in that it shows anti-oestrogenic effects or pro-
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oestrogenic effects that are cell type-specific [114,115].
Oestrogen receptors (ERs) are expressed in vascular
cells and mediate cardioprotective effects of oestro-
gens. However, Umetani et al. [114] have shown that
26-HC can act as a competitive antagonist of ER in
the vasculature leading to a loss of oestrogen protec-
tion towards vascular disease. ERs are also expressed
by breast cancer cells, and there is evidence that 26-
HC acts as a partial agonist in these cells [19,115,116].
Given that 26-HC is a direct product of cholesterol
metabolism, these findings have implications with
respect to breast cancer and hypercholesteraemic
women. In fact, Wu et al. found that in ER(+) breast
cancer (ER(+)BC) patients the 26-HC content of nor-
mal tissue was higher than that from controls, and
tumour 26-HC levels were further elevated [116]. In a
study published at almost exactly the same time, Nel-
son et al. [19] reported that in breast tissue CYP27A1
levels correlate with tumour grade. Nelson et al. [19]
showed that 26-HC stimulated ER(+)BC proliferation
through the ER and invasiveness through LXR. In a
later study, Nelson [117] proposed that inhibition of
CYP27A1 along with ERa and LXR antagonists could
increase the efficacy of treatments towards ER(+)BC.
Surprisingly, in the light of the discussion above, a
systematic review and meta-analysis of prospective
studies found a modest but statistically significant
inverse association between total cholesterol, more
specifically HDL cholesterol, and the risk of breast
cancer [118]. In addition, in a study of almost 300
breast cancer cases no association was found between
circulating 26-HC and breast cancer risk [119], and in
postmenopausal women, circulating 26-HC was associ-
ated with a lower risk of breast cancer [120]. Unfortu-
nately, the authors of these reports did not clarify
whether they were measuring the total 26-HC, that is
the sum of the inactive ester and the active nonesteri-
fied molecule or just the active nonesterified molecule.
The reader is left to guess, but in all probability a
reported value of about 200 nM (80 ngmL1) in
plasma refers to the total 26-HC. As discussed else-
where, there is a need for clarity in reporting of mass
spectrometry data [121].
Like 25-HC, nonesterified 26-HC has been suggested
to be an antiviral oxysterol [28]. Marcello et al., measur-
ing total 26-HC, found the plasma level of this oxysterol
in severely affected COVID-19 patients to be almost
half that in control subjects [28]. Serum levels of choles-
terol and its precursors were low in both moderate and
severe COVID-19 cases, possibly explaining reduced
levels of 26-HC. Notably, levels of antiviral 25-HC were
also reduced in severe COVID-19 cases, although the
reduction was not great (8.52  2.58 ngmL1 in
controls cf. 7.64  2.49 ngmL1 in severe cases).
Importantly, the reader should be reminded that total
sterols were being measured not the nonesterified bioac-
tive molecules.
Perhaps the reduced availability of cholesterol to
cells is a key aspect in the pathophysiology of
COVID-19 leading to reduced biosynthesis of antiviral
25-HC and 26-HC. However, based on studies suggest-
ing 25-HC is antiviral through reducing cholesterol
availability to membranes [29] it might be expected
that reduced serum cholesterol would be beneficial in
protection against COVID-19.
Key issue
Are total oxysterol levels a good surrogate measure for
concentrations of the nonesterified bioactive molecules?
As LCAT is abundant in HDL particles and will esterify
sterols, it not an unreasonable assumption that the
levels of esterified oxysterols are reflective of bioactive
nonesterified oxysterols exported from cells. However,
care should be taken when relating concentrations of
the total oxysterol measured in plasma to that required
for an in vitro or in vivo biological activity.
Cholestenoic acids: 3b-HCA, 3b,7a-dihydroxycholest-5-
en-(25R)26-oic (3b,7a-diHCA), 3b,7b-dihydroxycholest-
5-en-(25R)26-oic (3b,7b-diHCA) and 3b-hydroxy-7-
oxocholest-5-en-(25R)26-oic (3bH,7O-CA) acids
3b-HCA and 3b,7a-diHCA are intermediates in the
acidic pathway of bile acid biosynthesis [4,10], and
both these molecules, and the downstream metabolite
7a-hydroxy-3-oxocholest-4-en-(25R)26-oic acid
(7aH,3O-CA), are present in CSF and/or brain
[41,62,81]. Meaney et al. [122] have shown that
7aH,3O-CA provides a metabolic export route for 26-
HC from brain, which itself is imported to brain, and
is the first metabolite in the acidic pathway of bile acid
biosynthesis [4,10]. Both 3b-HCA and 3b,7a-diHCA
are LXR ligands, as are 3b,7b-diHCA and 3bH,7O-
CA, but not 7aH,3O-CA [18,113]. Interestingly, The-
ofilopoulos et al. showed that in the developing brain
3b,7a-diHCA promoted motor neuron survival in an
LXR-dependent manner, 3bH,7O-CA promoted matu-
ration of precursors into motor neurons, while 3b-
HCA was toxic, showing that cholestenoic acids dic-
tate the balance between life and death of motor neu-
rons [18]. In a more recent study, Abdel-Khalik et al.
[64] have shown that 3b,7b-diHCA and 3bH,7O-CA
activate Hh signalling by binding to Smo, highlighting
a further potential role for cholestenoic acids in devel-
opment.
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New ideas
In the light of the biological activity of 26-HC, 7a,26-
diHC and of the cholestenoic acids, we speculate that
the acidic pathway evolved as more than a pathway of
bile acid biosynthesis. The widespread expression of
CYP27A1 contrasts to that of liver-specific CYP7A1,
the first enzyme in the neutral pathway of bile acid
biosynthesis [4,10], and it may also be significant that
CYP27A1 is an inner mitochondrial enzyme, in contrast
to most other CYPs involved in cholesterol metabolism,
which are localised to the endoplasmic reticulum. We
suggest that the acidic pathway initially evolved to gen-
erate biologically active signalling molecules and its
development within hepatocytes provided the bonus of
bile acid formation to remove excess cholesterol and to
aid absorption in the intestine of dietary lipids. This
hypothesis is supported by the activity of the acidic
pathway during embryonic development [18,109] and
data that suggest that in infants the acidic pathway is
more important than the neutral pathway of bile acid
biosynthesis [123]. Kakiyama et al. [124] have proposed
a somewhat similar evolutionary role for bile acid
biosynthesis. They suggest that the acidic pathway
evolved as a mechanism to remove excess cholesterol
from the inner mitochondrial leaflet by CYP27A1 meta-
bolism to 26-HC, with further metabolism regulated by
endoplasmic reticulum-resident CYP7B1. They then
proposed that an inability of the acidic pathway to
increase the synthesis of bile acids without generating
toxic intermediates leads to evolution of the neutral
pathway starting with CYP7A1 and generating less-
toxic intermediates [124]. The two hypothesises differ in
that Kakiyama and Pandak focus on toxic intermedi-
ates and a requirement for a different and neutral path-
way [124], while we focus more on the positive effects of




There are two isomers of 5,6-EC with either 5a or 5b
stereochemistry. Both are formed by free radical oxida-
tion of cholesterol [11]. Both isomers can be hydrolysed
by the enzyme cholesterol epoxide hydrolase (ChEH,
EC:3.3.2.11) to cholestane-3b,5a,6b-triol. ChEH is an
unusual enzyme in that it made up of two subunits, each
of which is an enzymes in its own right, and part of the
cholesterol biosynthesis pathway, that is DHCR7 and
3b-hydroxysterol-D8-D7-isomerase (D8D7I, EC:5.3.3.5)
[125]. As mentioned above, cholestane-3b,5a,6b-triol is
elevated in the circulation people with Niemann–Pick
type C and type B disease and also those with lysosomal
acid lipase (LIPA, EC:3.1.1.13) deficiency, known as
Wolman disease when there is a complete absence of the
enzyme [48,68,126]. The origin of cholestane-3b,5a,6b-
triol is likely to be via hydrolysis of 5,6-EC, which is
also elevated in Niemann–Pick and in Wolman diseases
[48]. Cholestane-3b,5a,6b-triol can be metabolised via
multiple reactions to bile acids [48,69,70], or alterna-
tively oxidised by HSD11B2 to 3b,5a-dihydroxyc-
holestan-6-one (oncosterone, 3b,5a-diHC-6O). As the
trivial name oncosterone implies, 3b,5a-diHC-6O is a
tumour promoter (Fig. 3) [127].
Oncosterone has been shown to promote prolifera-
tion of mouse and human ER(+)BC and triple-nega-
tive breast cancer cell lines, and growth of breast
cancer tumours in vivo [127]. The proliferative effects
of oncosterone are through its activation of the gluco-
corticoid receptor (GR) [127]. Interestingly, corticos-
teroid ligands to GR do not share the proliferative
activities of oncosterone [9]. Oncosterone also acts as a
ligand to the LXR receptors, and it has been suggested
that the pro-invasive effects of oncosterone are medi-
ated by LXR [127].
An alternative route for metabolism of 5a,6-EC, but
not 5b,6-EC, is enzymatic conjugation with an amine
nucleophile. Two such nucleophiles showed to react
with 5a,6-EC in chemically catalysed reactions are his-
tamine and spermidine to give dendrogenin A (DDA)
and dendrogenin B (DDB), respectively. Both of these
metabolites have now been identified in mammalian
systems [128]. In contrast to oncosterone, DDA is
oncosuppressive. Importantly, DDA is not detected in
cancer cell lines, and its level in breast tissue is
decreased during oncogenesis [129]. The oncosuppres-
sive effects of DDA are at least part through activa-
tion of LXRb, inducing autophagy and cell
differentiation [130], while a second pathway is
through inhibition of ChEH and follow-on inhibition
of biosynthesis of oncosterone.
A Role in therapeutic development
The studies discussed above regarding metabolism of
5,6-EC indicate three potential targets for pharmaceu-
tical intervention:
1 The balance between cholestane-3b,5a,6b-triol and
oncosterone is dependent on the enzymes HSD11B2
and HSD11B1. Inhibition of HSD11B2 will reduce
the formation of oncosterone.
2 ChEH generates cholestane-3b,5a,6b-triol from 5,6-
EC. Inhibition of ChEH should reduce the forma-
tion of cholestane-3b,5a,6b-triol and consequently
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that of oncosterone. Likewise, inhibition of ChEH
should shunt 5a,6-EC towards the biosynthesis of
DDA that is oncosuppressive through LXRb.
3 A quite different idea is the upregulation of
CYP27A1. Assuming from the studies of Le Cornet
and coworkers that there is no correlation between
circulating 26-HC and breast cancer risk [119,120],
and in direct contrast to the suggestion of Nelson to
inhibit CYP27A1 [117], enhancing CYP27A1 expres-
sion or activity should drive cholestane-3b,5a,6b-
triol into the bile acid biosynthesis pathway and
away from metabolism by HSD11B2 to oncos-
terone. These ideas are yet to be tested.
22R-hydroxycholesterol (22R-HC)
Cholesterol is converted to 22R-HC by CYP11A1
(EC:1.14.15.6). Like CYP27A1, CYP11A1 is a resident
of the innermitochondrial membrane. CYP11A1 can
then convert 22R-HC to 20R,22R-dihydroxycholes-
terol (20R,22R-diHC) and ultimately the C21 steroid,
pregnenolone. These reactions may or may not pro-
ceed with the release of the oxysterol intermediates
[131,132]. Like other side-chain oxysterols, 22R-HC is
a ligand to LXRs and an inhibitor of SREBP-2 pro-
cessing to its active form [51,52]. The metabolism of
20R-HC and 20R,22R-diHC to bile acids rather than
steroids is another story yet to be told.
Cholesterol precursors and their
oxysterol derivatives
The hypothesis that the acidic pathway evolved to
generate biologically active intermediates can be
extended to include the Kandutsch–Russell and Bloch
pathways of sterol biosynthesis. Lanosterol, the first
sterol, has been shown to stimulate INSIG-mediated
degradation of HMGCoA reductase (HMGCR, EC:1.
1.1.34), the enzyme catalysing the rate-determining
step of cholesterol synthesis, and remarkably, 26-hy-
droxylanosterol, also called 27-hydroxylanosterol, is
10 times more potent [133]. Other sterols in the Kan-
dutsch–Russell and Bloch pathways with 4,4-dimethyl
groups were shown to similarly accelerate the degra-
dation of HMGCR, as does 25-HC [133,134]. Lanos-
terol does not repress the SREBP-2 activation of
cholesterol biosynthesis, but in contrast to initial data
[133], other 4,4-dimethyl sterols are reported to inhibit
SREBP-2 activation [134]. At the other end of the
cholesterol biosynthesis pathway from lanosterol,
desmosterol inhibits the processing of SREBP-2 and
acts as a ligand towards LXRs [135]. As discussed
above, desmosterol acts as a substrate for CYP46A1
generating biologically active 24S,25-EC [106], which
can also be formed in a shunt of the Bloch pathway
[105]. 7-DHC, the final member of the Kandutsch–
Russell pathway, is also a source of bioactive metabo-
lites, and these may be formed enzymatically, or via
free radical reactions, 7-DHC being particularly sus-
ceptible to nonenzymatic oxidation. For example,
3b,5a-dihydroxycholest-7-en-6-one, formed by hydrol-
ysis and oxidation of 7-dehydrocholesterol-5a,6-epox-
ide, is a Hh pathway antagonist binding to Smo at a
site distinct from the CRD and the cyclopamine
pocket [136]. As discussed earlier, 7-DHC can be con-
verted to 7-OC by CYP7A1 [80], and this opens a
route to 7b-HC and multiple biologically active oxys-
terols [22,64,137].
Fig. 3. 5,6-EC at the fulcrum of protection against and the proliferation of cancer.
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Conclusions
Oxysterols and other intermediates in the bile acid
biosynthesis pathways have interested sterol chemists
for decades [13]. It appears that while the neutral path-
way of bile acid biosynthesis generates intermediates
with comparatively little biological activity, the reverse
appears to be the case with the acidic pathway. The
prominence of the acidic pathway in early life high-
lights the importance of its intermediates, and as sug-
gested above, it is tempting to speculate that the acidic
pathway evolved to generate and regulate biologically
active molecules, and its utilisation by hepatocytes
provided an added bonus of generating bile acids.
Besides the acidic pathway, other pathways to bile
acids, and also to steroid hormones, generate bioactive
intermediates. In which case, progression towards bile
acids may also be a way of regulating lipokine biosyn-
thesis and metabolism in specific cell types and tissues,
for example CYP46A1 is expressed in brain; CH25H
in activated immune cells; and CYP11A1 in sex organs
and the adrenal gland. In contrast to these three
enzymes, CYP27A1, initiating the acidic pathway, and
CYP7B1 acting as the 7a-hydroxylase in this pathway
are rather ubiquitously expressed and can be ‘lent’ to
the different bile acid biosynthesis pathway to help
regulate the formation/metabolism of the active inter-
mediates (Fig. 4). Of course, an ultimate function of
bile acid formation is also to remove excess choles-
terol.
Bile acids can also be synthesised from oxysterols
generated by nonenzymatic reactions. Incredibly, inter-
mediates in these pathways also have biological activ-
ity. While 7-OC and 7b-HC can also be formed
enzymatically, an enzyme to generate 5,6-EC has yet
to be isolated. Is there one, or has the pathway from
5,6-EC evolved exclusively to remove products of
cholesterol oxidation formed by reactive oxygen spe-
cies?
The multiple pathways to bile acids provide redun-
dancy in the biological system with many intermedi-
ates sharing similar activities, and this is probably the
reason why most of the inborn errors of bile acid
biosynthesis are not fatal, and the equivalent knockout
mice are viable. However, these inborn errors do lead
to disease indicating the imperfection of the back-up
system.
The huge range of bile acid intermediates, the cross-
over of pathways, sharing of enzymes, shuttling of
oxysterols between different organelles, cell types and
Fig. 4. The acidic pathway of bile acid biosynthesis generates bioactive intermediates. Key enzymes in this pathway, CYP27A1 and
CYP7B1, can be lent to different bile acid biosynthesis pathways to similarly generate and regulate other lipokines.
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tissues make this a fascinating field to work in, with
still many important discoveries to be made.
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